Prelude Therapeutics Incorporated PRLD
Set alert
3.88 USD -0.22 -5.37%
At close · Oct 30
3.85 -0.03 -0.77%
After hours · Oct 30, 6:59 PM ET
3.82 Day range 4.11
1.19 52-week range 6.63
- YTD
- +33.79%
- 1 year
- +147.13%
- Open
- 4.01
- Prev close
- 4.10
- Mkt cap
- 309.02M
- Vol
- 218.10K
- Avg vol
- 494.54K
- EPS
- -0.73
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.82
- High
- 4.11
- Forward P/E
- -0.82
- Beta
- 1.55
- Short ratio
- 7.51
- Inst. own
- 84.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 1.23
- 200-d avg
- 3.50
- 1y target
- 5.00
1D chart
Signals (20)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | 3:50 PM | 1 day ago |
| MACD: Buy Signal | 3:49 PM | 1 day ago |
| SMA: Bullish | 3:46 PM | 1 day ago |
| MACD: Sell Signal | 3:39 PM | 1 day ago |
| RSI: Overbought | 3:25 PM | 1 day ago |
| SMA: Bullish | 3:15 PM | 1 day ago |
| SMA: Bearish | 3:13 PM | 1 day ago |
| SMA: Bullish | 3:11 PM | 1 day ago |
| MACD: Buy Signal | 2:45 PM | 1 day ago |
| RSI: Oversold | 2:37 PM | 1 day ago |
| RSI: Oversold | 2:17 PM | 1 day ago |
| RSI: Oversold | 1:59 PM | 1 day ago |
| MACD: Sell Signal | 1:35 PM | 1 day ago |
| MACD: Buy Signal | 12:46 PM | 1 day ago |
| MACD: Sell Signal | 12:42 PM | 1 day ago |
| MACD: Buy Signal | 12:17 PM | 1 day ago |
| MACD: Sell Signal | 12:11 PM | 1 day ago |
| MACD: Buy Signal | 12:08 PM | 1 day ago |
| MACD: Sell Signal | 11:49 AM | 1 day ago |
| SMA: Bearish | 11:32 AM | 1 day ago |
Key statistics
- Market cap
- 68.24M
- Enterprise value
- -63.94M
- Trailing P/E
- 0.00
- Forward P/E
- -0.82
- PEG ratio
- 0.00
- Price / sales
- 22.75
- Price / book
- 0.44
- EPS (TTM)
- -1.77
- Beta
- 1.55
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.00M
- Revenue growth
- 0.00%
- Free cash flow
- -61.55M
- Total cash
- 153.63M
- Total debt
- 18.14M
- Return on equity
- -66.64%
- Shares outstanding
- 42.18M
- Short % of float
- 17.63%
- 50-day average
- 1.23
- 200-day average
- 3.50
Analyst view
Consensus: hold
Hold
Price target (mean) 5.00 +28.9% upside
Now 3.88
- Target (low)
- 1.00
- Target (mean)
- 5.00
- Target (high)
- 10.00
Ratings (0m) 5 3 buy · 0 hold · 2 sell
- Strong buy2
- Buy1
- Hold0
- Sell1
- Strong sell1
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.46725.
Financials — quick view
PRLD Revenue — quarterly 5.70M
PRLD Net income — quarterly -13.92M
PRLD EPS — quarterly -0.14
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.48 | -0.43 | +0.05 | +10.42% |
| Aug 12, 2024 | Jun 1, 2024 | -0.46 | -0.46 | 0.00 | 0.00% |
| Aug 12, 2024 | Jun 1, 2024 | -0.46 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.47 | -0.42 | +0.05 | +10.64% |
| May 7, 2024 | Mar 1, 2024 | -0.47 | — | — | — |
| Feb 15, 2024 | Dec 1, 2023 | -0.50 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | up | Neutral | Buy |
| Sep 16, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Sep 16, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- preludetx.com
News
- Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
- Prelude Therapeutics to Participate in the Chardan Healthcare Conference
- Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
- Prelude Therapeutics Enters Clinical Trial Collaboration And Supply Agreement With Eli Lilly For Supply Of Its CDK4/6 Kinase Inhibitor, Abemaciclib And Its Oral Estrogen Receptor Antagonist Imlunestrant
- Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
- Head to Head Review: Surrozen (NASDAQ:SRZN) and Prelude Therapeutics (NASDAQ:PRLD)
- Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock Rated “Moderate Buy” by Sell-Side Analysts
- JP Morgan Initiates Coverage On Prelude Therapeutics with Overweight Rating, Announces Price Target of $12
- Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Prelude Therapeutics Receives FDA Clearance To Proceed With A Phase 1 Study Under Its Investigational New Drug Application For PRT13722 For The Treatment Of Patients With HR+/HER2- Breast Cancer; Expects To Begin Enrolling Patients In Q4 2026
Your note
Sign in to keep a note on PRLD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BONITA DAVID P. M.D. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 21, 2023 | 0 |
| CHARDONNET LAURENT | Chief Financial Officer | Purchase | May 22, 2023 | 42,165 |
| HUANG JANE | President | Conversion of Exercise of derivative security | Oct 3, 2024 | 63,341 |
| LIM BRYANT DAVID | Chief Financial Officer | Purchase | Dec 18, 2024 | 27,400 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 21, 2023 | 0 |
| VADDI KRISHNA | Chief Executive Officer | Purchase | Dec 18, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 30.14% | 16,589,442 | 20.57M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 18.40% | 10,123,824 | 12.55M | Sep 29, 2024 |
| Deerfield Management Company, L.P. (Series C) | 6.84% | 3,766,120 | 4.67M | Sep 29, 2024 |
| Boxer Capital, LLC | 3.10% | 1,708,187 | 2.12M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 1.99% | 1,097,599 | 1.36M | Sep 29, 2024 |
| Blackrock Inc. | 1.92% | 1,058,316 | 1.31M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Health Sciences Fund | 1.47% | 809,844 | 1.00M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 1.31% | 720,427 | 893.33K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.65% | 358,702 | 444.79K | Oct 30, 2024 |
| MFS New Discovery Fund | 0.60% | 327,699 | 406.35K | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 0.38% | 207,507 | 257.31K | Sep 29, 2024 |
| Price (T.Rowe) Small-Cap Value Fund | 0.32% | 178,089 | 220.83K | Sep 29, 2024 |